Cathinone derivatives: A review of their chemistry, pharmacology and toxicology

Drug Testing and Analysis

Volumn 3, Issue 7-8, 2011, Pages 439-453

  Kelly, John P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Cathinone derivatives; Chemistry; Khat; Pharmacology; Toxicology

Indexed keywords

DRUG PRODUCTS;

ACTIVE CONSTITUENTS; CATHINONE; CATHINONE DERIVATIVE; IN-VITRO; KHAT; LEGAL STATUS; PHARMACOLOGY; PUBLIC CONCERN; TOXICOLOGY; VITRO AND IN VIVO;

INDIUM COMPOUNDS;

1 NAPTHALEN 2 YL 2 PYRROLIDIN 1 YL PENTAON 1 ONE; 2 (METHYLAMINO) 1 (3 BROMOPHENYL)PROPAN 1 ONE; 2 (METHYLAMINO) 1 (4 BROMOPHENYL)PROPAN 1 ONE; 2 (PROPYLAMINO) 1 PHENYLPROPAN 1 ONE; 2 (TERT BUTYLAMINO) 1 PHENYLPROPAN 1 ONE; 2 FLUOROMETHCATHIONE; 2 METHYLAMINO 1 PHENYLBUTAN 1 ONE; 3 FLUOROMETHCATHIONE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 FLUOROMETHCATHIONE; 4 METHOXY ALPHA PYRROLIDINOPROPIOPHENONE; 4 METHYL ALPHA PYRROLIDINOHEXIOPHENONE; 4 METHYL ALPHA PYRROLIDINOPROPIOPHENONE; 4 METHYL N ETHYLCATHINONE; 4' METHYLMETHCATHINONE; ALPHA PHTHALIMIDOPROPIOPHENONE; ALPHA PYRROLIDINOPROPIOPHENONE; AMFEBUTAMONE; AMPHETAMINE; CATHA EDULIS EXTRACT; CATHINONE; COCAINE; DIETHYLPROPRION; METHAMPHETAMINE; METHCATHINONE; METHYLONE; N ETHYLCATHINONE; N,N DIMETHYLCATHINONE; PYROVALERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE TOXICITY; CHEMISTRY; CHRONIC TOXICITY; COUGHING; DEPRESSION; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG PURITY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG USE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOBACCO DEPENDENCE;

EID: 79960634938     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.313     Document Type: Review

References (165)

1. A.M. Feyissa, J.P. Kelly, A review of the neuropharmacological properties of khat. Prog. Neuropsychopharmacol. Biol. Psychiat. 2008, 32, 1147.
2. E.E. Balint, G. Falkay, G.A. Balint, Khat-a controversial plant. Wien Klin. Wochenschr. 2009, 121, 604.
3. A. Gebissa, Khat in the horn of Africa: Historical perspectives and current trends. J. Ethnopharmacol. 2010, 132, 607.
4. A.D. Krikorian, Khat and its use: an historical perspective. J. Ethnopharmacol. 1984, 12, 115.
5. G. Cox, R. Rampes, Adverse effects of khat: a review. Adv. Psychiat. Treat. 2003, 9, 456.
6. O. Wolfes, Über das Vorkommen von d-nor-iso-Ephedrin in Catha edulis. Arch. der Pharmazie, 1930, 268, 81.
7. J.F. Hyde, E. Browning, R. Adams, Synthetic Homologs of d, l-Ephedrine. J. Am. Chem. Soc. 1928, 50, 2287.
8. J. Saem de Burnaga Sanchez, Sur un homologue de l'ephedrine. Bull. Soc. Chim. Fr. 1929, 45, 284.
9. N.V. Cozzi, K.F. Foley, Methcathinone is a substrate for the serotonin uptake transporter. Pharmacol. Toxicol. 2003, 93, 219.
10. L.L. Ioannides-Demos, L. Piccenna, J.J. McNeil, Pharmacotherapies for obesity: past, current, and future therapies. J. Obes. (in press).
11. D.W. Peterson, C.K. Maitai, S.B. Sparler, Relative potencies of two phenylalkylamines found in the abused plant catha edulis, khat. Life Sci. 1980, 27, 2143.
12. K. Szendrei, The chemistry of khat. Bull. Narcotics 1980, 32, 5.
13. H. Schorno, R. Brenneisen, E. Steinegger, Qualitative und quantitative Untersuchungen über das Vorkommen ZNS-aktiver Phenylpropylamine in Handelsdrogen und über deren Verteilung in verschidenen Organ van Catha edulis. Pharm. Act. H. 1982, 57, 168.
14. J. DeRuiter, L. Hayes, A. Valaer, C.R. Clarke, Methcathinone and designer analogues: synthesis, stereochemical analysis, and analytical properties. J. Chromatogr. Sci. 1994, 32, 552.
15. P. Jacob, A.T. Shulgin, Neurobiological Technologies, Inc., USA. Patent WO9639133 1996, 19. CA 126:117961.
16. M.G. Bossong, J.P. Van Dijk, R.J. Niesink, Methylone and mCPP, two new drugs of abuse? Addiction Biology 2005, 10, 321.
17. F. Westphal, T. Junge, P. Rosner, G. Fritschi, B. Klein, U. Girreser, Mass spectral and NMR spectral data of two new designer drugs with an α-aminophenone structure: 4′-Methyl-α-pyrrolidinohexanophenone and 4′-methyl-α-pyrrolidinobuyrophenone. Forens. Sci. Int. 2007, 169, 32.
18. R.P. Archer, Fluoromethcathinone, a new substance of abuse. Forens. Sci. Int. 2009, 185, 10.
19. S.D. Brandt, H.R. Sumnall, F. Measham, J. Cole, Analyses of second-generation 'legal highs' in the UK: Initial findings. Drug Test. Analysis 2010, 2, 377.
20. T.M. Brunt, A. Poortman, R.J.M. Niesink, W. van den Brink, Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. (in press).
21. F. Measham, K. Moore, R. Newcombe, Z. Welch, Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs and Alcohol Today 2010, 10, 14.
22. EMCDDA, The state of the drugs problem in Europe. EMCDDA: Lisbon, Portugal, 2009.
23. EMCDDA, Council decision of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures (2010/759/ EU). Available at: accessed 21st January, 2011.
24. M. Odenwald, N. Warfa, K. Bhui, T. Elbert, The stimulant khat-another door in the wall? A call for overcoming the barriers. J. Ethnopharmacol. 2010, 132, 615.
25. A. Klein, P. Metal, A good chew or good riddance-how to move forward in the regulation of khat consumption. J. Ethnopharmacol. 2010, 132, 584.
26. J. Beyer, F.T. Peters, T. Kraemer, H.H. Maurer, Detection and validated quantification of nine herbal phenalkylamines and methcathinone in human blood plasma by LC-MS/MS with electrospray ionization. J. Mass Spectrom. 2007, 42, 150.
27. D.M. Wood, S. Davies, M. Puchnarewicz, J. Button, R. Archer, H. Ovaska, J. Ramsey, T. Lee, D.W. Holt, P.I. Dargan, Recreational use of mephedrone (4-methylcathinone, 4-MMC) with associated sympathomimetic toxicity. J. Med. Toxicol. 2010, 6, 327.
28. K. Morris, UK places generic ban on mephedrone drug family. Lancet 2010, 375, 1333.
29. P.I. Dargan, S. Albert, D.M. Wood, Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010, 103, 875.
30. EMCDDA, Synthetic cathinones. Available at: accessed 21st January, 2011.
31. T.A. Dal Cason, The characterization of some 3, 4-methyl-enedioxycathinone (MDCATH) homologs. Forens. Sci. Int. 1997, 87, 9.
32. A. Camilleri, M.R. Johnston, M. Brennan, S. Davis, D.G.E. Caldicott, Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluor-methamphetamine, α-phthalimidopropiophenone and N-ethylcathinone. Forens. Sci. Int. 2010, 197, 59.
33. H. Bejhadj-Tahar, N. Sadeg, Methcathinone: a new postindustrial drug. Forens. Sci. Int. 2005, 153, 99.
34. K.F. Foley, N.V. Cozzi, Novel aminopropiophenones as potential antidepressants. Drug Devel. Res. 2003, 60, 252.
35. F. Schifano, A. Albanese, S. Fergus, J.L. Stair, P. Deluca, O. Corazza, Z. Davey, J. Corkery, H. Siemann, N. Scherbaum, M. Farre, M. Torrens, Z. Demetrovics, A.H. Ghodse, Psychonaut Web Mapping and ReDNet Research Groups, Mephedrone (4-methylmethcathinone; "meow meow"): chemical, pharmacological and clinical issues. Psychopharmacology (in press).
36. K.O. Haustein, Bupropion: pharmacological and clinical profile in smoking cessation. Int. J. Clin. Pharmacol. Ther. 2003, 41, 56.
37. H.T. Kamata, N. Shima, K. Zaitsu, T. Kamata, A. Miki, M. Nishikawa, M. Katagi, H. Tsuchihashi, Metabolism of the recently encountered designer drug, methylone in humans and rats. Xenobiotica 2006, 36, 709-723.
38. M.R. Meyer, H.H. Maurer, Metabolism of designer drugs of abuse: an updated review. Curr. Drug Metab. 2010, 11, 468.
39. S.D. Brandt, R.C.R. Wootton, G. De Paoli, S. Freeman, The naphyrone story: the alpha or beta-naphthyl isomer? Drug Test. Analysis 2010, 2, 496.
40. M. Wikstrom, G. Thelander, I. Nystrom, R. Kronstrand, Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J. Anal. Toxicol. 2010, 34, 594.
41. H.H. Maurer, T. Kraemer, D. Springer, R.F. Staack, Chemistry, pharmacology, toxicology and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidonophenone types: a synopsis. Ther. Drug Mon. 2004, 26, 127.
42. D. Springer, G. Fritschi, H.H. Maurer, Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-a-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. J. Chromatog. B. 2003, 796, 253.
43. D. Springer, G. Fritschi, H.H. Maurer, Metabolism and toxicological detection of the new designer drug 4′-methoxy-α-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J. Chromatog. B. 2003, 793, 331.
44. H.S. Shin, Y.S. Shin, S. Lee, B.B. Park, Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J. Anal. Toxicol. 1996, 20, 568.
45. C. Sauer, F.T. Peters, C. Haas, M.R. Meyer, G. Fritschi, H.H. Maurer, New designer drug a-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 2009, 44, 952.
46. F. Westphal, T. Junge, P. Rosner, F. Sonnichsen, F. Schuster, Mass and NMR spectroscopic characterization of 3, 4-methylenedioxypyrolvalerone: a designer drug with a-pyrrolidinophenone structure. Forens. Sci. Int. 2009, 190, 1.
47. S.D. Brandt, S. Freeman, H.R. Sumnall, F. Measham, J. Cole, Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. Drug Test. Analysis (in press).
48. K. Zaitsu, M. Katagi, H. Kamata, T. Kamata, N. Shima, A. Miki, H. Tsuchihashi, Y. More, Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forens. Sci. Int. 2009, 188, 131.
49. S. Gibbons, M. Zloh, An analysis of the 'legal high' mephedrone. Bioorg. Med. Chem. Lett. 2010, 20, 4135.
50. S. Geisshusler, R. Brenneisen, The content of psychoactive phenylpropyl and phenylpentenyl khatamines in Catha edulis Forsk. of different origin. J. Ethnopharmacol. 1987, 19, 269.
51. J.S. Chappell, M.M. Lee, Cathinone preservation in khat evidence via drying. Forens. Sci. Int. 2010, 195, 108.
52. Y. Bentur, A. Bloom-Krasik, B. Raikhlin-Eisenkraft, Illicit cathinone ("Hagigat") poisoning. Clin Toxicol. 2008, 46, 206.
53. R. Chintalova-Dallas, P. Case, N. Kitsenko, Z. Lazzarini, Boltushka: A homemade amphetamine-type stimulant and HIV risk in Odessa. Int. J. Drug Policy 2009, 20, 347.
54. K.L. Windahl, M.J. McTigue, J.R. Pearson, S.J. Pratt, J.E. Rowe, E.M. Sear, Investigation of the impurities found in methamphetamine synthesised from pseudoephedrine by reduction with hydriodic acid and red phosphorus. Forens. Sci. Int. 1995, 76, 97.
55. L. Karila, M. Reynaud, GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test. Analysis (in press).
56. P.V. Kavanagh, S. McNamara, D. Angelov, S. McDermott, D. Mullan, S.A. Ryder, The characterization of 'legal highs" available from Head Shops in Dublin. Available at: accessed 30th June, 2010.
57. S. Davies, D.M. Wood, G. Smith, J. Button, J. Ramsey, R. Archer, D.W. Holt, P.I. Dargan, Purchasing "legal highs" on the internet-is there consistency in what you get. Q. J. M. 2010, 103, 489.
58. E. Shimizu, H. Watanabe, T. Kojima, H. Hagiwara, M. Fujisaki, R. Miyatake, K. Hashimoto, M. Iyo, Combined intoxication with methylone and 5-MeO-MIPT. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 288-291.
59. U.D. McCann, D.F. Wong, F. Yokoi, V. Villemagne, R.F. Dannals, G.A. Ricaurte, Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with (11C)WIN-35, 428. J. Neurosci. 1998, 18, 8417.
60. F.A. Sawair, A. Al-Mutwakel, K. Al-Eryani, A. Al-Surhy, S. Maruyama, J. Cheng, A. Al-Sharabi, T. Saku, High relative frequency of oral squamous cell carcinoma in Yemen: qat and tobacco chewing as its aetiological background. Int. J. Environ. Health Res. 2007, 17, 185.
61. S.W. Toennes, S. Harder, M. Schramm, C. Niess, G.F. Kauert, Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. Br. J. Clin. Pharmacol. 2003, 56, 125.
62. I. Dhaifalah, J. Santavy, Khat habit and its health effect. A natural amphetamine. Biomed. Papers 2004, 148, 11.
63. R. Brenneisen, H.U. Fisch, U. Koelbing, S. Geisshusler, P. Kalix, Amphetamine-like effects in humans of the khat alkaloid cathinone. Br. J. Clin. Pharmacol. 1990, 30, 825.
64. D. James, R.D. Adams, R. Spears, G. Cooper, D.J. Lupton, J.P. Thompson, S.H.L. Thomas, Clinical characteristics of mephedrone toxicity reported to the UK national poisons information service. Emerg. Med. J. (in press).
65. R. Newcombe, Mephedrone: The use of mephedrone (M-cat, Meow) in Middlesborough. Lifeline Publications: Manchester, UK, 2009.
66. P. Widler, K. Mathys, R. Brenneisen, P. Kalix, H.U. Fisch, Pharma-codynamics and pharmacokinetics of khat: a controlled study. Clin. Pharmacol. Ther. 1994, 55, 556.
67. S.W. Toennes, G.F. Kauert, Excretion and detection of cathinone, cathine, and phenylpropanolamine in urine after kath chewing. Clin. Chem. 2002, 48, 1715.
68. A.N. Guantai, C.K. Maitai, Metabolism of cathinone to d norpseudoephedrine in humans. J. Pharm. Sci. 1983, 72, 1217.
69. K. Mathys, R. Brenneisen, Determination of (S)-(-)-cathinone and its metabolites (R, S)-(-)-norephedrine and (R, R)-(-)-norpseudoephedrine in urine by high-performance liquid chromatography with photodiode-array detection. J. Chromatog. 1992, 593, 79.
70. T.S. Emerson, J.E. Cisek, Methcathinone: a Russian designer amphetamine infiltrates the rural Midwest. Ann. Emerg. Med. 1993, 22, 1897.
71. M.R. Meyer, J. Wilhelm, F.T. Peters, H.H. Maurer, Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone and methylone in urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 2010, 397, 1225.
72. K. Zaitsu, M. Katagi, H.T. Kamata, A. Miki, H. Tsuchihashi, Discrimination and identification of regioisomeric β-keto analogues of 3, 4-methylenedioxyamphetamines by gas chromatography-mass spectrometry. Forens. Toxicol. 2008, 26, 45.
73. D. Springer, F.T. Peters, G. Fritschi, H.H. Maurer, Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J. Chromatog. B. 2002, 773, 25.
74. D. Springer, F.T. Peters, G. Fritschi, H.H. Maurer, New designer drug 4′-methyl-α-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatog. B. 2003, 789, 79.
75. D. Springer, G. Fritschi, H.H. Maurer, Metabolism and toxicological detection of the new designer drug 3′, 4′-methylenedioxy-α-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatog. B. 2003, 793, 377.
76. F. Westphal, P. Rosner, T. Junge, Differentiation of regioisomeric ring-substituted fluorophenethylamines with product ion spectrometry. Forens. Sci. Int. 2010, 194, 53.
77. ACMD, Consideration of the cathinones. Advisory Council on the Misuse of Drugs 2010.
78. C. Sanchez, J. Hyttel, Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol. Neurobiol. 1999, 19, 467.
79. N.V. Cozzi, M.K. Sievert, A. Shulgin, P. Jacob, A.E. Ruoho, Inhibition of plasma membrane membrane monoamine transporters by β-ketoamphetamines. Eur. J. Pharmacol. 1999, 381, 63.
80. P.C. Meltzer, D. Butler, J.R. Deschamps, B.K. Madras, (4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49, 1420.
81. F.I. Carroll, B.E. Blough, P. Abraham, A.C. Mills, J.A. Holleman, S.A. Wolckenhauer, A.M. Decker, A. Landavazo, K.T. McElroy, H.A. Navarro, M.B. Gatch, M.J. Forster, Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J. Med. Chem. 2009, 52, 6768.
82. P. Kalix, Effect of the alkaloid (-)-cathinone on the release of radioactivity from rat striatal tissue prelabelled with 3H-serotonin. Neuropsychobiology 1984, 12, 127.
83. P. Kalix, R.A. Glennon, Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem. Pharmacol. 1986, 35, 3015.
84. M.P. Gygi, A.E. Fleckenstein, J.W. Gibb, G.R. Hanson, Role of endogenous dopamine in the neurochemical deficits induced by methcathinone. J. Pharmacol. Exp. Ther. 1997, 283, 1350.
85. R.B. Rothman, N. Vu, J.S. Partilla, B.L. Roth, S.J. Hufeisen, B.A. Compton-Toth, J. Birkes, R. Young, R.A. Glennon, In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J. Pharmacol. Exp. Ther. 2003, 307, 138-145.
86. J.L. Zelger, H.X. Schorno, E.A. Carlini, Behavioural effects of cathinone, an amine obtained from Catha edulis Forsk.: comparisons with amphetamine, norpseudoephedrine, apomorphine and nomifensine. Bull. Narc. 1980, 32, 67.
87. J.L. Zelger, E.A. Carlini, Influence of cathinone (alpha-aminopropiophenone) and cathine (phenylpropanolamine) on circling behavior and on the uptake and release of 3H dopamine in striatal slices of rats. Neuropharmacology 1981, 20, 39.
88. M.Y. Banjaw, W.J. Schmidt, Catha edulis extract and its active principle cathinone induce ipsilateral rotation in unilaterally lesioned rats. Behav. Pharmacol. 2006, 17, 615.
89. P. Nencini, G. Amiconi, O. Befani, M.A. Abdullahi, M.C. Anania, Possible involvement of amine oxidase inhibition in the sympathetic activation induced by khat (Catha edulis) chewing in humans. J. Ethnopharmacol. 1984, 11, 79.
90. M. Osorio-Olivares, M.C. Rezende, S. Sepúlveda-Boza, B.K. Cassels, A. Fierro, MAO inhibition by arylisopropylamines: the effect of oxygen substituents at the beta-position. Bioorg. Med. Chem. 2004, 12, 4055.
91. E.A. Pehek, M.D. Schechter, B.K. Yamamoto, Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo. Neuropharmacology 1990, 29, 1171.
92. G. Ellison, Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry. Eur. Neuropsychopharmacol. 2002, 12, 287.
93. M.Y. Banjaw, W.J. Schmidt, Behavioural sensitisation following repeated intermittent oral administration of Catha edulis in rats. Behav. Brain Res. 2005, 156, 181.
94. L. Cleary, J.R. Docherty, Actions of amphetamine derivatives and cathinone at the noradrenaline transporter. Eur. J. Pharmacol. 2003, 476, 31.
95. G.C. Wagner, K. Preston, G.A. Ricaurte, C.R. Schuster, L.S. Seiden, Neurochemical similarities between d, l-cathione and d-amphetamine. Drug Alcohol Depend. 1982, 9, 279.
96. J.A. Nielsen, M.D. Schechter, Behavioral and neurochemical effects of (-)- and (+/-) -cathinone: dose-response and time-course. Prog. Neuropsychopharmacol. Biol. Psychiatry 1985, 9, 739.
97. A.E. Fleckenstein, H.M. Haughey, R.R. Metzger, J.M. Kokoshka, E.L. Riddle, J.E. Hanson, J.W. Gibb, G.R. Hanson, Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur. J. Pharmacol. 1999, 382, 45.
98. P. Nencini, A.M. Ahmed, Khat consumption: a pharmacological review. Drug Alcohol Depend. 1989, 23, 19.
99. N.B. Patel, Mechanism of action of cathinone: the active ingredient of khat (Catha edulis). East Afr. Med. J. 2000, 77, 329.
100. D. Kebede, A. Alem, G. Mitike, F. Enquselassie, F. Berhane, Y. Abebe, R. Ayele, W. Lemma, T. Assefa, T. Gebremichael, Khat and alcohol use and risky sex behaviour among in-school and out-of-school youth in Ethiopia. BMC Public Health 2005, 5, 1.
101. C. Pantelis, C.G. Hindler, J.C. Taylor, Use and abuse of khat (Catha edulis): a review of the distribution, pharmacology, side effects and a description of psychosis attributed to khat chewing. Psychol. Med. 1989, 19, 657.
102. R.J. Nielen, F.M. van der Heijden, S. Tuinier, W.M. Verhoeven, Khat and mushrooms associated with psychosis. World J. Biol. Psychiatry 2004, 5, 49.
103. M. Odenwald, F. Neuner, M. Schauer, T. Elbert, C. Catani, B. Lingenfelder, H. Hinkel, H. Hafner, B. Rockstroh, Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia. BMC Med. 2005, 12, 3.
104. M. Odenwald, Chronic khat use and psychotic disorders: a review of the literature and future prospects. Sucht 2007, 53, 9.
105. M.S. Bimerew, F.C. Sonn, W.P. Kortenbout, Substance abuse and the risk of readmission of people with schizophrenia at Amanuel Psychiatric Hospital, Ethiopia. Curationis 2007, 30, 74.
106. S.L. Patel, S. Wright, A. Gammampila, Khat use among Somalis in four English cities (Home Office Online Report 47/05). Available at: accessed on 30th January, 2011.
107. W. Sykes, N. Coleman, P. Desai, C. Groom, M. Gure, R. Howarth, Research Report 44, Key implications, Perceptions of the social harms associated with khat use. Available at accessed on 30th January, 2011.
108. E.J. Pennings, A. Opperhuizen, J.G. van Amsterdam, Risk assessment of khat use in the Netherlands: a review based on adverse health effects, prevalence, criminal involvement and public order. Regul. Toxicol. Pharmacol. 2008, 52, 199.
109. N. Numan, Exploration of adverse psychological symptoms in Yemeni khat users by the Symptoms Checklist-90 (SCL-90). Addiction 2004, 99, 61.
110. W. Eckersley, R. Salmon, M. Gebru, Driver impairment and road traffic injuries: a view from Ethiopia. Bull. World Health Organ. 2010, 88, 235.
111. A. Feigin, P. Higs, M. Hellard, P. Dietze, Further research required to determine link between khat consumption and driver impairment. Bull. World Health Organ. 2010, 88, 480.
112. M. Teitler, S. Leonhardt, N.M. Appel, E.B. De Souza, R.A. Glennon, Receptor pharmacology of MDMA and related hallucinogens. Ann. N. Y. Acad. Sci. 1990, 600, 626.
113. M.S. Goldstone, 'Cat': methcathinone-a new drug of abuse. J. Am. Med. Assoc. 1993, 269, 2508.
114. P. Nencini, C.E. Johanson, C.R. Schuster, Sensitization to kappa opioid mechanisms associated with tolerance to the anorectic effects of cathinone. J. Pharmacol. Exp. Ther. 1988, 245, 147.
115. P. Kalix, O. Braenden, Pharmacological aspects of the chewing of khat leaves. Pharmacol. Rev. 1985, 37, 149.
116. S. McNamara, S. Stokes, C. Coleman, Head shop compound abuse among attendees of the drug treatment centre board. Irish Medical Journal 2010, 103, 136.
117. M. Saleh, H. Mekkawy, F. el-Komy, Acute effects of a khat extract on the rat electroencephalogram. J. Ethnopharmacol. 1988, 23, 291.
118. M.Y. Banjaw, K. Miczek, W.J. Schmidt, Repeated Catha edulis oral administration enhances the baseline aggressive behavior in isolated rats. J. Neural Transm. 2006, 113, 543.
119. R. Gugelmann, M. von Allmen, R. Brenneisen, H. Porzig, Quantitative difference in the pharmacological effects of (+)- and (-)-cathinone. Experientia 1985, 15, 1568.
120. R.A. Glennon, R. Young, B.R. Martin, T.A. Dal Cason, Methcathinone ('Cat'): an enantiomeric potency comparison. Pharmacol. Biochem. Behav. 1995, 50, 601.
121. M. Sparago, J. Elos, J. Yuan, G. Hatzidimitrou, J. Tolliver, T.A. Dal Cason, J. Katz, G.J. Ricaurte, Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J. Pharmacol. Exp. Ther. 1996, 279, 1043.
122. W.B. Gentry, A.U. Ghafoor, W.D. Wessinger, E.M. Laurenzana, H.P. Hendrickson, S.M. Owens, (+)-methamphetamine-induced spontaneous behaviour in rats depends on route of (+)METH administration. Pharmacol. Biochem. Behav. 2004, 79, 751.
123. F. Dunne, A. O'Halloran, J.P. Kelly, Development of a home cage locomotor tracking system capable of detecting the stimulant and sedative properties of drugs in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31, 1456.
124. M.G. McNamara, J.P. Kelly, B.E. Leonard, Some behavioural and neurochemical aspects of subacute ( ± ) 3, 4 methylenedioxymethamphetamine administration in rats. Pharmacol. Biochem. Behav. 1995, 52, 479.
125. F. Borsini, A. Meli, Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 1988, 94, 147.
126. R.C. Pierce, P.W. Kalivas, A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Brain Res Rev. 1997, 25, 192.
127. M.Y. Banjaw, M. Fendt, W.J. Schmidt, Clozapine attenuates the locomotor sensitisation and the prepulse inhibition deficit induced by repeated oral administration of Catha edulis extract and cathinone in rats. Behav. Brain Res. 2005, 160, 365.
128. R.A. Glennon, M. Yousif, N. Naiman, P. Kalix, Methcathinone: a new and potent amphetamine-like agent. Pharmacol. Biochem. Behav. 1987, 26, 547.
129. R. Young, R.A. Glennon, Cocaine-stimulus generalization to two new designer drugs: methcathinone and 4-methylaminorex. Pharmacol. Biochem. Behav. 1993, 45, 229.
130. C.N. Jones, J.L. Howard, S.T. McBennett, Stimulus properties of antidepressants in the rat. Psychopharmacology 1980, 67, 111.
131. R.J. Lamb, R.R. Griffiths, Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofenac and imipramine. Psychopharmacology 1990, 102, 183.
132. B.J. Kaminski, R.R. Griffiths, Intravenous self-injection of methcathinone in the baboon. Pharmacol. Biochem. Behav. 1994, 47, 981.
133. B.A. Gosnell, J.M. Yracheta, S.M. Bell, K.E. Lane, Intravenous self administration of cathinone by rats. Behav. Pharmacol. 1996, 7, 526.
134. T. Yanagita, Intravenous self-administration of (-)-cathinone and 2-amino-1-(2, 5-dimethoxy-4-methyl)phenylpropane in rhesus monkeys. Drug Alcohol Depend. 1986, 17, 135.
135. M. Abdulwaheb, E. Makonnen, A. Debella, D. Abebe, Effect of Catha edulis Forsk (khat) extracts on male rat sexual behavior. J. Ethnopharmacol. 2007, 110, 250.
136. S.A. Taha, A.M. Ageel, M.W. Islam, O.T. Ginawi, Effect of (-)-cathinone, a psychoactive alkaloid from khat (Catha edulis forsk.) and caffeine on sexual behaviour in rats. Pharmacol. Res. 1995, 31, 299.
137. D. Gustavsson, C. Escher, Mephedrone-internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance. Lakartidningen 2009, 106, 2769.
138. D.M. Wood, S.L. Greene, P.I. Dargan, Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg. Med. J. 2011, 28, 280.
139. Europol-EMCDDA, Joint report on a new psychoactive substance: 4-methylmethcathinone (mephedrone). Available at: accessed 24th June, 2010.
140. A.J. Dickson, S.P. Vorce, B. Levine, M.R. Past, Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J. Anal. Toxicol. 2010, 34, 162.
141. H. Torrance, G. Cooper, The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forens. Sci. Int. 2010, 202, e62.
142. R. Hoffman, M. Al'absi, Khat use and neurobehavioural functions: suggestions for future studies. J. Ethnopharmacol. 2010, 132, 554.
143. P.K. Morrish, N. Nicolaou, P. Brakkenberg, P.E. Smith, Leukoencephalopathy associated with khat misuse. J. Neurol. Neurosurg. Psychiat. 1999, 67, 556.
144. R.M. Gladstone, A.P. Strafella, J-H, Jo, A.E. Lang, Manganese-induced parkinsonism associated with methcathinone (ephedrone) abuse. Arch. Neurol. 2007, 64, 886.
145. A. Stepens, I. Logira, V. Liguts, P. Aldins, I. Eksteina, A. Platkajis, I. Martinosone, E. Terauds, B. Rozentale, M. Donaghy, A parkinsonian syndrome in methcathinone users and the role of manganese. New Eng. J. Med. 2008, 358, 1009.
146. C. Colosimo, M. Guidi, Parkinsonism due to ephedrone neurotoxicity: a case report. Eur. J. Neurol. 2009, 16, e114.
147. K. Sikk, P. Taba, S. Haldre, J. Berquist, D. Nyholm, H. Askmark, T. Danfors, J. Sorensen, L. Thurfjell, R. Raininko, R. Eriksson, R. Flink, C. Farnstrand, S-M. Aquilonious, Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure. Acta Neurol. Scand. 2010, 121, 237.
148. R.M. De Bie, R.M. Gladstone, A.P. Strafella, J.H. Ko, A.E. Lang, Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. Arch. Neurol. 2007, 64, 886.
149. F. Varlibas, I. Delipoyraz, G. Yuksel, G. Filiz, H. Tireli N.O. Gecim, Neurotoxicity following chronic intravenous use of "Russian Cocktail". Clin. Toxicol. 2008, 14, 1.
150. T.R. Guilarte, Manganese and Parkinson's disease: a critical review and new findings. Environ. Health Perspect. 2010, 118, 1071.
151. M.P. Gygi, J.W. Gibb, G.R. Hanson, Methcathinone: an initial study of its effects on monoaminergic systems. J. Pharmacol. Exp. Ther. 1996, 276, 1066.
152. V.C. Freund-Michel, M.A. Birrell, H.J. Patel, I.M. Murray-Lyon, M.G. Belvisi, Modulation of cholinergic contractions of airway smooth muscle by cathinone: potential beneficial effects in airway diseases. Eur. Respir. J. 2008, 32, 579.
153. C.D. Murray, C.W. Le Roux, A.V. Emmanuel, J.M. Halkaet, A.M. Przyborowska, M.A. Kamm, I.M. Murray-Lyon, The effect of khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion. Subst. Use Misuse 2008, 43, 762.
154. N.A. Hassan, A.A. Gunaid, F.M. El-Khally, I.M. Murray-Lyon, The effect of chewing Khat leaves on human mood. Saudi Med. J. 2002, 23, 850.
155. S. Gardos, J.O. Cole, Evaluation of pyrovalerone in chronically fatigued volunteers. Curr. Ther. Res. 1971, 13, 631.
156. A.J. Giannini, N.S. Miller, C.E. Turner, Treatment of khat addiction. J. Subst. Abuse Treat. 1992, 9, 379.
157. D.L. Browne, Qat use in New York City. N. IDA Res. Monogr. 1990, 105, 464.
158. F.I. Carroll, B.E. Blough, S.W. Mascarella, H.A. Navarro, J.B. Eaton, R.J. Lukas, M.I. Damaj, Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J. Med. Chem. 2010, 53, 2204.
159. R.J. Lukas, A.Z. Muresan, M.I. Damaj, B.E. Blough, X. Huang, H.A. Navarro, S.W. Mascarella, J.B. Eaton, S.K. Marxer-Miller, F.I. Carroll, Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J. Med. Chem. 2010, 53, 4731.
160. WHO, WHO Expert Committee on Drug Dependence. World Health Organ Tech. Rep. Serv. 2006, 942, 1.
161. P. Griffiths, D. Lopez, R. Sedefov A. Gallegos B. Hughes A. Noor L. Royuela, Khat use and monitoring drug use in Europe: The current situation and issues for the future. J. Ethnopharmacol. 2010, 132, 578.
162. ACMD, Khat (Qat): Assessment of risk to the individual and communities in the UK. Advisory Council on the Misuse of Drugs, 2005.
163. Z. Kmietowicz, Home secretary bans mephedrone after taking advice from depleted council. BMJ 2010, 340, c1784.
164. A. Klein, S. Beckerleg, D. Hailu, Regulating khat-dilemmas and opportunities for the international drug control system. Int. J. Drug Policy 2009, 20, 509.
165. Anon, A collapse in the integrity of scientific advice in the UK. Lancet 2010, 375, 1319.